SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-20-005292
Filing Date
2020-04-22
Accepted
2020-04-22 16:45:38
Documents
7
Period of Report
2020-04-22
Effectiveness Date
2020-04-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A oysterpoint-2020proxystate.htm DEF 14A 483644
2 card11.jpg GRAPHIC 113668
3 card21.jpg GRAPHIC 97645
4 image_01.jpg GRAPHIC 12495
5 image_11.jpg GRAPHIC 4574
6 image_21.jpg GRAPHIC 3620
7 image_31.jpg GRAPHIC 131
  Complete submission text file 0001628280-20-005292.txt   804925
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39112 | Film No.: 20808345
SIC: 2836 Biological Products, (No Diagnostic Substances)